Clinical Trials Logo

Rectal Cancer clinical trials

View clinical trials related to Rectal Cancer.

Filter by:
  • Enrolling by invitation  
  • « Prev · Page 2

NCT ID: NCT02751736 Enrolling by invitation - Rectal Cancer Clinical Trials

The Effect Of Probiotics On Bowel Function Restoration After Ileostomy Closure In Patients With Rectal Cancer

Start date: April 2016
Phase: N/A
Study type: Interventional

The study will investigate whether Probiotics(CJLP243) given just before and after ileostomy repair operation in patient with rectal cancer improve a bowel function.

NCT ID: NCT02488707 Enrolling by invitation - Rectal Cancer Clinical Trials

Minimally Invasive Sphincter Sparing Total Mesorectal Excision for Ultra-low Rectal Cancer After Initial Chemo-radiotherapy (MISS-TRICR).

MISS-TRICR
Start date: February 2014
Phase: Phase 2
Study type: Interventional

A prospective study is planned for management of low rectal cancer with the aim of sphincter preservation and improving the oncological outcome of the patients, through comparing of both approaches minimally invasive techniques including transanal total mesorectal excision and laparoscopic intersphincteric resection.

NCT ID: NCT02153853 Enrolling by invitation - Obesity Clinical Trials

Does Obesity Increase the Risk of Conversion and Short Term Complications in Laparoscopic Rectal Surgery?

Start date: June 2014
Phase: N/A
Study type: Observational

Obesity is on the rise in the Western population and BMI has been shown to be associated with an increased risk of per- and postoperative complications. The investigators intend to study a population of more than 300 patients undergoing laparoscopic surgery for rectal cancer. The investigators main outcome measure will be the conversion rate, and the investigators also intend to study other indications of short term complications, such as peroperative bleeding, infection, re-operation and mortality. The investigators hypothesise that increased BMI does not increase the risk of conversion.

NCT ID: NCT01755585 Enrolling by invitation - Cervical Cancer Clinical Trials

Irradiation Modulates the Pharmacokinetics of Anticancer Drugs

Start date: July 2011
Phase: N/A
Study type: Observational

Radiation therapy (RT) is used as an effective local treatment modality to inhibit cell proliferation, induce cell death and suppress tumor growth. To improve the treatment outcome, in terms of both locoregional control and survival, the concurrent use of chemotherapy during radiation therapy (CCRT) is now the standard treatment for various malignancies, especially locally advanced cancers. Among the drugs used to enhance RT effect, 5-fluorouracil (5-FU) is one of the most commonly used chemotherapeutic agents of CCRT. In the past, RT was solely used as a local treatment and its effect was estimated by local effect model. However, growing evidence shows that irradiation has direct DNA damage-dependent effects as well as sending signals to neighboring cells. Recently, we reported that abdominal irradiation could significantly modulate the systemic pharmacokinetics of 5-FU at 0.5 Gy, off-target area in clinical practice, and at 2 Gy, the daily treatment dose for target treatment in an experimental rat model. Additionally, the results from a clinical investigation showed that colorectal cancer patients with lower AUC of 5-FU during adjuvant chemotherapy had lower disease-free survival. Taken together, these lines of evidence support the importance and necessity to search for the mediators responsible for the unexpected effect of local RT on systemic pharmacokinetics of chemotherapeutic agents, such as 5-FU. In the present study, the investigators investigated whether the phenomena and mechanism of RT-PK is a fact for different anticancer drugs in human.